Cargando…

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis

Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenneck, Claudia, Novak, Natalija
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/
https://www.ncbi.nlm.nih.gov/pubmed/18488075
_version_ 1782155229555326976
author Jenneck, Claudia
Novak, Natalija
author_facet Jenneck, Claudia
Novak, Natalija
author_sort Jenneck, Claudia
collection PubMed
description Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed.
format Text
id pubmed-2386357
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-23863572008-05-16 The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis Jenneck, Claudia Novak, Natalija Ther Clin Risk Manag Review Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed. Dove Medical Press 2007-06 2007-06 /pmc/articles/PMC2386357/ /pubmed/18488075 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Jenneck, Claudia
Novak, Natalija
The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title_full The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title_fullStr The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title_full_unstemmed The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title_short The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
title_sort safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/
https://www.ncbi.nlm.nih.gov/pubmed/18488075
work_keys_str_mv AT jenneckclaudia thesafetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis
AT novaknatalija thesafetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis
AT jenneckclaudia safetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis
AT novaknatalija safetyandefficacyofalefaceptinthetreatmentofchronicplaquepsoriasis